TY - JOUR
T1 - Transcatheter mitral valve repair for functional mitral regurgitation
T2 - Evaluating the evidence
AU - Gelijns, Annetine C.
AU - Moskowitz, Alan J.
AU - O'Gara, Patrick T.
AU - Giustino, Gennaro
AU - Mack, Michael J.
AU - Mancini, Donna M.
AU - Bagiella, Emilia
AU - Hung, Judy
AU - Ailawadi, Gorav
AU - Leon, Martin B.
AU - Acker, Michael A.
AU - Alexander, John H.
AU - Dickert, Neal W.
AU - Taddei-Peters, Wendy C.
AU - Miller, Marissa A.
N1 - Funding Information:
Dr O'Gara discloses nonfinancial support: Medtronic Apollo Executive Committee and Edwards Lifesciences, Executive Committee, Early TAVR. Dr Mack discloses nonfinancial support: Edwards Lifesciences, Medtronic, and Abbott. Gorav Ailawadi discloses personal fees: Abbott, Edwards Lifesciences, Medtronic, Admedus, and Gore. Dr Alexander discloses institutional grant support from the National Institutes of Health (NIH) related to the CT Surgery Network and acknowledges that his institution, Duke University, is the data center for the TVT Registry. All other authors have nothing to disclose with regard to commercial support. Dr Giustino discloses grants from the NIH / National Heart, Lung, and Blood Institute (NHBLI) Cardiothoracic Surgical Trials Network. Dr Leon discloses grants from Medtronic and Edwards Lifesciences. Drs Moskowitz, Bagiella, and Gelijns disclose grants from the National Heart, Lung, and Blood Institute . The Cardiothoracic Surgical Trials Network is supported by a cooperative agreement ( U01 HL088942 ) funded by the NHLBI . The views expressed in this article are those of the authors and do not necessarily represent the views of the NHLBI, NIH, or US Department of Health and Human Services.
Funding Information:
Dr O'Gara discloses nonfinancial support: Medtronic Apollo Executive Committee and Edwards Lifesciences, Executive Committee, Early TAVR. Dr Mack discloses nonfinancial support: Edwards Lifesciences, Medtronic, and Abbott. Gorav Ailawadi discloses personal fees: Abbott, Edwards Lifesciences, Medtronic, Admedus, and Gore. Dr Alexander discloses institutional grant support from the National Institutes of Health (NIH) related to the CT Surgery Network and acknowledges that his institution, Duke University, is the data center for the TVT Registry. All other authors have nothing to disclose with regard to commercial support. Dr Giustino discloses grants from the NIH/National Heart, Lung, and Blood Institute (NHBLI) Cardiothoracic Surgical Trials Network. Dr Leon discloses grants from Medtronic and Edwards Lifesciences. Drs Moskowitz, Bagiella, and Gelijns disclose grants from the National Heart, Lung, and Blood Institute. The Cardiothoracic Surgical Trials Network is supported by a cooperative agreement (U01 HL088942) funded by the NHLBI. The views expressed in this article are those of the authors and do not necessarily represent the views of the NHLBI, NIH, or US Department of Health and Human Services.
Publisher Copyright:
© 2020
PY - 2021/11
Y1 - 2021/11
N2 - Objectives: Two trials (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation Trial and Percutaneous Repair with the MitraClip Device for Severe Functional/Secondary Mitral Regurgitation Trial) were published in 2018 evaluating the effectiveness and safety of transcatheter repair for patients with heart failure with significant functional mitral regurgitation, which yielded different results. This article reviews the strength of the evidence, differences in trial designs, ethical and implementation implications, and delineates future research needs to help guide the appropriate dissemination of transcatheter repair for functional patients with mitral regurgitation. Methods: The National Heart, Lung, and Blood Institute convened a workshop of interdisciplinary experts to address these objectives. Results: Transcatheter repair of functional mitral regurgitation can provide significant benefits in terms of heart failure hospitalizations, survival, and quality of life when appropriate heart failure candidates with moderate to severe or severe mitral regurgitation while on optimal guideline-directed medical therapy can be identified. Key ingredients for success are preoperative evaluation and management and postoperative care by an interdisciplinary heart team. Conclusions: Given the discordance observed between trials, ongoing innovation in patient management, and potential expansion of indications for use, the evidence base must be expanded to optimize appropriate implementation of this complex therapy. This will require more complete capture of outcome data in real-world settings for all eligible candidates whether or not they receive this therapy. Inevitably, the indications for use of this therapy will expand, as will the devices and therapeutic approaches for this population, necessitating the study of comparative effectiveness through randomized trials or observational studies. Moreover, given the substantial variations in care delivery, conducting implementation research to delineate characteristics of the optimal care model would be of benefit.
AB - Objectives: Two trials (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation Trial and Percutaneous Repair with the MitraClip Device for Severe Functional/Secondary Mitral Regurgitation Trial) were published in 2018 evaluating the effectiveness and safety of transcatheter repair for patients with heart failure with significant functional mitral regurgitation, which yielded different results. This article reviews the strength of the evidence, differences in trial designs, ethical and implementation implications, and delineates future research needs to help guide the appropriate dissemination of transcatheter repair for functional patients with mitral regurgitation. Methods: The National Heart, Lung, and Blood Institute convened a workshop of interdisciplinary experts to address these objectives. Results: Transcatheter repair of functional mitral regurgitation can provide significant benefits in terms of heart failure hospitalizations, survival, and quality of life when appropriate heart failure candidates with moderate to severe or severe mitral regurgitation while on optimal guideline-directed medical therapy can be identified. Key ingredients for success are preoperative evaluation and management and postoperative care by an interdisciplinary heart team. Conclusions: Given the discordance observed between trials, ongoing innovation in patient management, and potential expansion of indications for use, the evidence base must be expanded to optimize appropriate implementation of this complex therapy. This will require more complete capture of outcome data in real-world settings for all eligible candidates whether or not they receive this therapy. Inevitably, the indications for use of this therapy will expand, as will the devices and therapeutic approaches for this population, necessitating the study of comparative effectiveness through randomized trials or observational studies. Moreover, given the substantial variations in care delivery, conducting implementation research to delineate characteristics of the optimal care model would be of benefit.
KW - functional mitral regurgitation
KW - mitral valve
KW - randomized trial
KW - transcatheter mitral valve repair
UR - http://www.scopus.com/inward/record.url?scp=85083891979&partnerID=8YFLogxK
U2 - 10.1016/j.jtcvs.2020.02.132
DO - 10.1016/j.jtcvs.2020.02.132
M3 - Article
C2 - 32359794
AN - SCOPUS:85083891979
SN - 0022-5223
VL - 162
SP - 1504
EP - 1511
JO - Journal of Thoracic and Cardiovascular Surgery
JF - Journal of Thoracic and Cardiovascular Surgery
IS - 5
ER -